Open-label Study to Investigate the Safety, Tolerability, PK, and Pharmacodynamics of the AKT Inhibitor GSK690693
Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This study is a first time in human, Phase I, open-label study to determine recommended doses
and schedules, based on maximum tolerated doses and biologically active doses, for the AKT
inhibitor GSK690693.